Hi Traders and Investors,
It’s been six months since Trump returned to the White House—and the impact on markets is already taking shape.
From new policy rollouts to shifting economic priorities, we’re entering a new phase of opportunity for investors who know where to look.
That’s why we’ve just released a brand-new report:
"5 Best Stocks to Buy Under Trump’s Presidency"
[Download Your Free Report Here]
Inside, you’ll discover:
-
Which sectors are showing early momentum under the new administration
-
5 stocks uniquely positioned for potential long-term gains
-
Strategic insights to help align your portfolio with today’s evolving landscape
The market doesn’t wait—and neither should you.
Now’s the time to get positioned while many investors are still adjusting.
[Access the Report: 5 Stocks for Trump’s America]
Best regards,
The Investment News Daily Team
(By following any of the links above, you're choosing to opt in to receive insightful updates from The Investment News Daily + 2 free bonus subscriptions! Your privacy is important to us. You can unsubscribe anytime. See our privacy policy for details.)
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Written by Chris Markoch. Published 9/17/2025.
Key Points
- Viking stock is down, but still has major upside in the obesity drug market.
- ImmunityBio advances Anktiva beyond bladder cancer with new trial results.
- Maze Therapeutics rallies on early-stage data with more catalysts ahead.
Investing in biotechnology stocks can be challenging because of the intricate science behind drug candidates. They tend to be highly volatile, frequently posting double-digit swings in both directions.
Long term, biotech stocks can offer an attractive risk-reward profile. For patient investors willing to hold through clinical trials, these three stocks could deliver substantial payoffs.
Viking: An Obesity Challenger with Big Upside
The best Buffett-style stocks are the ones he can't buy (Ad)
Warren Buffett is the greatest value investor of all time. But even the Oracle of Omaha has limits.
Because of Berkshire Hathaway's size, Buffett simply can't invest in small-cap stocks without taking controlling stakes. That means some of the market's most promising companies are completely off his radar.
But they don't have to be off yours.
We've put together a brand-new report profiling 5 small-cap stocks that check all the boxes of Buffett's investing criteria solid financials, durable business models, strong management, and clear growth catalysts.
The only difference?
These stocks are flying under Wall Street's radar and still accessible to individual investors like you.
Viking Therapeutics Inc. (NASDAQ: VKTX) rallied in 2024 alongside the surge in GLP-1 weight loss drugs.
However, in 2025 the stock has slid over 40%, including a 20% drop after its August clinical trial update. The trial showed an average 12.2% weight loss among patients—far from a failure.
Investors were rattled by the fact that weight loss occurred at the highest dose, whereas competitors report similar or superior results at lower doses. A 28% dropout rate further raised concerns about potential side effects.
Is that enough to justify such a steep decline? Analysts disagree, issuing a consensus price target of $87.50, implying roughly 270% upside from current levels.
The obesity drug market is vast and can support more players beyond the two giants—Novo Nordisk and Eli Lilly. That makes this an opportune moment for conviction investors to start accumulating shares.
On the charts, VKTX appears to be bottoming. Its relative strength index (RSI) sits around 34—nearing oversold territory—while the MACD hints that bearish momentum is fading. After the death cross formed in late August, investors should watch for a potential golden cross as a signal of renewed strength.
ImmunityBio: A Penny Stock with Serious Potential
ImmunityBio Inc. (NASDAQ: IBRX) has climbed roughly 8.4% in 2025, with most gains coming in the past month. The catalyst? In late August, the company disclosed that all five patients in its pilot glioblastoma study "attained 100% disease control" using a regimen that includes its ANKTIVA drug.
ANKTIVA earned FDA approval in April 2024 for bladder cancer and is now being evaluated for other cancers. ImmunityBio is also exploring its use as a potential treatment for HIV and Long COVID.
This broad utility makes it one of the most exciting immunotherapy drugs in development.
Analysts assign a consensus price target of $10.75, implying over 280% upside. Still, caution may be prudent: IBRX trades above its 200-day SMA and sports an RSI of 76—a level at which the stock has historically met resistance.
While investors might wait for a pullback before adding shares, the long-term thesis is intact: if ANKTIVA demonstrates efficacy across multiple indications, IBRX could graduate from penny stock status to biotech heavyweight.
Maze Therapeutics: Early Success in Rare Diseases
Maze Therapeutics Inc. (NASDAQ: MAZE) began trading publicly in February 2025. Since then, the shares are up roughly 86%, and analysts see further upside.
On Sept. 11, Maze announced positive Phase 1 results for its lead candidate MZE782, an oral SLC6A19 inhibitor showing proof of mechanism in treating phenylketonuria (PKU) and chronic kidney disease (CKD). That paves the way for a Phase 2 trial.
Despite years of development and no guarantee of approval, analysts remain optimistic. HC Wainwright leads the bullish pack with a $50 price target, implying roughly 2× upside from current levels.
Such parabolic moves often warrant caution: MAZE's RSI is approaching overbought territory, though it recently found support near $22.40. A sustained hold above that level would signal bullish momentum.
Maze offers exposure to rare disease therapeutics—an area with strong pricing power and limited competition. Continued clinical progress could support further gains.
This email message is a sponsored email for Darwin, a third-party advertiser of MarketBeat. Why was I sent this message?.
If you need help with your account, please feel free to email our South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2025 MarketBeat Media, LLC.
345 N Reid Place #620, Sioux Falls, SD 57103. United States of America..